The contract manufacturing organisation (CMO) said the analytical services expansion will support ‘more projects’, but did not specify how many. The firm did say that the lab will be operational and fully compliant with ICH, EU and FDA GMP in May 2013.
Maria Lundberg, General Manager at Recipharm Pharmaceutical Development. “Our analytical development service is already an integrated and vital part of the pharmaceutical development work, and this investment will enable our business to continue to grow, creating more flexibility and a better service offering.
News of the investment follows just a few months after Recipharm secured a €90m loan with Swedbank AB and said it would pursue strategic acqusitions and invest in capacityies that enhance customer relationships.
The following month the Swedish CMO invested in filling capacity at a facility it operates in France.